Post-Marketing Surveillance (Usage Results Study) of Fruzaqla Capsule (Fruquintinib) for the Approved Indications in South Korea
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age greater than or equal to (\>=)18 years.
• Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea.
• Participant voluntarily consent to participate in the study.
Locations
Other Locations
Republic of Korea
Yonsei University Hospital
RECRUITING
Seoul
Contact Information
Primary
Takeda Contact
medinfoUS@takeda.com
+1-877-825-3327
Time Frame
Start Date: 2025-09-29
Estimated Completion Date: 2031-03-01
Participants
Target number of participants: 600
Treatments
All Study Participants
Data will be collected for participants with metastatic colorectal cancer (mCRC) who will receive Fruzaqla according to the approved indication as per the Physician's routine schedule.
Related Therapeutic Areas
Sponsors
Leads: Takeda